Sanofi re­struc­tures US com­mer­cial vac­cines sales force

Sanofi is over­haul­ing its US com­mer­cial op­er­a­tions for its vac­cines and will cut an undis­closed num­ber of jobs, the com­pa­ny con­firmed to End­points News.

The move fol­lows some big R&D changes in CEO Paul Hud­son’s push to start a new chap­ter at the French phar­ma. Hud­son has set out to in­crease the com­pa­ny’s Phase 3 pipeline by 50% over the next two years and be­come an “im­munol­o­gy pow­er­house.”

While the com­pa­ny re­cent­ly high­light­ed vac­cines as one of its key pri­or­i­ties, a spokesper­son said Thurs­day that it’s “im­ple­ment­ing a stream­lined strate­gic sales struc­ture.” The spokesper­son de­clined to pro­vide fur­ther in­for­ma­tion on the changes that will be made, the time­frame, and the num­ber of em­ploy­ees im­pact­ed.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER